autologous keratinocytes in platelet-rich plasma

This investigational autologous cell therapy was developed by the Centre Hospitalier Universitaire Vaudois (CHUV) in Switzerland for the treatment of skin graft donor site wounds. The therapy consists of a patient's own keratinocytes (epidermal skin cells) isolated from a small biopsy and subsequently suspended in autologous platelet-rich plasma (PRP). When applied topically to a wound bed, the PRP acts as a biological scaffold and a source of essential growth factors and cytokines (such as PDGF, TGF-beta, and VEGF) that stimulate cellular proliferation and tissue repair. The keratinocytes provide the cellular basis for rapid re-epithelialization. Clinical evaluation in a Phase I trial demonstrated that this combination significantly accelerates the healing of split-thickness skin graft donor sites and reduces patient pain compared to standard paraffin gauze dressings.

Other names

autologous keratinocytes suspended in platelet concentrateskeratinocyte suspension in platelet-rich plasmaautologous keratinocytes in platelet concentrate